^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (HER2 inhibitor, γδ TCR modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Published date:
10/16/2023
Excerpt:
The ongoing clinical trial (NCT04727151) is evaluating the safety and preliminary anti-tumor activity of TAC01-HER2 treatment of HER2+ solid tumors....A 67% disease control rate (DCR) was observed in Cohorts 2-4 at 4 weeks restaging after TAC01-HER2 infusion….Treatment with TAC01-HER2 showed manageable safety and promising clinical activity in a heavily pre-treated cancer population.
Trial ID:
